rTMS联合药物治疗抑郁症的临床疗效观察

Observation of the Clinical Efficacy of rTMS Combined with Drugs in the Treatment of Depression

摘要: 目的：探讨rTMS分别联合盐酸帕罗西汀片和盐酸度洛西汀肠溶片对改善抑郁症的临床疗效，为优化抑郁症治疗方案提供依据。方法：选取2023年1月1日~2023年9月30日就诊于吉林市第六人民医院确诊为抑郁症的住院患者98名，入组患者依据不同治疗分案进行分组：rTMS + 帕罗西汀组及帕罗西汀组、rTMS + 度洛西汀组及度洛西汀组。统计分析各组患者组间及组内HAMD量表评分及有效率；当P < 0.05，认为具有统计学差异。结果：收集rTMS + 帕罗西汀组及帕罗西汀组两组患者入院当天(0天)、入院1周、2周、3周HAMD评分。统计分析结果显示，两组患者治疗后HAMD评分均存在3周连续性下降；且都存在组内差异(F = 48.245, P < 0.01; F = 33.429, P < 0.01)；治疗3周时两组间差异具有统计学意义(t = −2.073, P = 0.044)。联合rTMS可提升治疗有效率17.40%。收集rTMS + 度洛西汀组及度洛西汀组两组患者入院当天(0天)、入院1周、2周、3周HAMD评分。统计分析结果显示，两组患者治疗后HAMD评分均存在3周连续性下降；且都存在组内差异(F = 56.946, P < 0.01; F = 56.688, P < 0.01)；治疗3周时两组间差异具有统计学意义(t = −2.309, P < 0.05)。联合rTMS可提升治疗有效率9.09%。结论：rTMS联合药物治疗可改善抑郁症临床症状同时有效提高患者治疗的有效率。

Abstract: Objective: To investigate the clinical efficacy of rTMS combined with paroxetine hydrochloride tablets and duloxetine hydrochloride enteric-coated tablets in improving depression respectively, and to provide a basis for optimizing the treatment of depression. Methods: A total of 98 inpatients diagnosed with depression in Jilin Sixth People’s Hospital from January 1, 2023 to September 30, 2023 were enrolled, and the enrolled patients were divided into different treatment groups: rTMS + paroxetine group and paroxetine group, rTMS + duloxetine group and duloxetine group. The scores and effective rates of HAMD scales between and within groups were statistically analyzed. When P < 0.05, it is considered statistically different. Results: The HAMD scores of patients in the rTMS + paroxetine group and paroxetine group were collected on the day of admission (0 day), 1 week, 2 weeks, and 3 weeks of admission. The results of statistical analysis showed that the HAMD score of the two groups decreased continuously for 3 weeks after treatment. There were intra-group differences (F = 48.245, P < 0.01; F = 33.429, P < 0.01), and there were statistically significant differences between the two groups at 3 weeks of treatment (t = −2.073, P = 0.044). Combined with rTMS, the effective rate of treatment was increased by 17.40%. The HAMD scores of the rTMS + duloxetine group and the duloxetine group were collected on the day of admission (0 day), 1 week, 2 weeks, and 3 weeks of admission. The results of statistical analysis showed that the HAMD score of the two groups decreased continuously for 3 weeks after treatment. There were intra-group differences (F = 56.946, P < 0.01; F = 56.688, P < 0.01), and there were statistically significant differences between the two groups at 3 weeks of treatment (t = −2.309, P < 0.05). Combined with rTMS, the effective rate of treatment was increased by 9.09%. Conclusion: rTMS combined with drug therapy can improve the clinical symptoms of depression and effectively increase the effectiveness rate of treatment in patients.